المؤلفون: Haiyan Xue, Lan Wang, Yuliang Ma, Chang Hou

المصدر: BMC Cardiovascular Disorders, Vol 24, Iss 1, Pp 1-5 (2024)

مصطلحات موضوعية: MINOCA, Olverembatinib, TKI, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1471-2261Test

الوصول الحر: https://doaj.org/article/444ae3f024d3493ebf796405c80a716aTest

المؤلفون: Jianghua Ding, Wen Li

المصدر: Frontiers in Pharmacology, Vol 14 (2023)

مصطلحات موضوعية: olverembatinib, elderly, philadelphia chromosome, B-cell, acute lymphoblastic leukemia, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fphar.2023.1320641/fullTest; https://doaj.org/toc/1663-9812Test

الوصول الحر: https://doaj.org/article/5a7d65568d214045b429d0c3f0e0a540Test

المؤلفون: Honglan Qian, Dongxu Gang, Xiaoyu He, Songfu Jiang

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: olverembatinib, chronic myeloid leukemia, tyrosine kinase inhibitors, breakpoint cluster region protein and abelson tyrosine-protein kinase 1, T315I mutation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2022.1036437/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/f64df5eaf56f4047833f88b7ea030076Test

المؤلفون: Marina Chan, Eric C Holland, Taranjit S Gujral

المصدر: EMBO Molecular Medicine, Vol 14, Iss 6, Pp n/a-n/a (2022)

مصطلحات موضوعية: cytokine storm, SARS‐CoV‐2, Omicron variant, Olverembatinib, kinase signaling, Medicine (General), R5-920, Genetics, QH426-470

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/1757-4676Test; https://doaj.org/toc/1757-4684Test

الوصول الحر: https://doaj.org/article/6db57cf13dcf4a5ea8ffcda770ae370cTest

المؤلفون: Malik, Sara, Hassan, Shahzeb, Eskazan, Ahmet Emre

مصطلحات موضوعية: Asciminib, chronic myeloid leukemia, flumatinib, HQP1351, K0706, novel therapies, olverembatinib, PF-114, tyrosine kinase inhibitor, vodobatinib, Therapy

العلاقة: Expert Review Of Hematology; Diğer; https://doi.org/10.1080/17474086.2021.1990034Test; https://hdl.handle.net/20.500.12831/6155Test; WOS:000709318500001; 2-s2.0-85117284689; PubMed: 34608829

الإتاحة: https://doi.org/10.1080/17474086.2021.1990034Test
https://doi.org/20.500.12831/6155Test
https://hdl.handle.net/20.500.12831/6155Test

المؤلفون: Oziskender, Renan, Eskazan, Ahmet Emre

مصطلحات موضوعية: Olverembatinib, Chronic myeloid, leukemia, Tyrosine kinase inhibitors, Hematologic , malignancies, T315I mutation, Abl Kinase, Resistance, Inhibitor, Ponatinib

العلاقة: Drugs Of Today; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1358/dot.2022.58.11.3441854Test; https://hdl.handle.net/20.500.12831/12105Test; 58; 11; 531; 538; WOS:000893954700001; 2-s2.0-85141981568

الإتاحة: https://doi.org/10.1358/dot.2022.58.11.3441854Test
https://doi.org/20.500.12831/12105Test
https://hdl.handle.net/20.500.12831/12105Test

المصدر: Treatment With Olverembatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Failed to at Least Two Previously Administered Second-generation Tyrosine Kinase Inhibitors: a Prospective, Single-arm Clinical Trial.

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05311943Test